Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Most mechanistic/clinical claims are broadly consistent with the provided label excerpts for indication and LVOT/filling pressures, but many other claims (e.g., specifics on monitoring, dosing adjustments, underpowered heart, and outflow obstruction reduced excessively) are not supported by the provided label text excerpts, and full safety/dosing/precaution sections were not provided for verification.
Category Scores
Accurate Statements
Mavacamten is a medicine used to treat hypertrophic cardiomyopathy (HCM).
Supported generally by indication excerpt describing obstructive HCM (Section 1 INDICATIONS AND USAGE).
Mavacamten is used to treat obstructive hypertrophic cardiomyopathy (obstructive HCM).
Section 1 INDICATIONS AND USAGE: indicated for adults with symptomatic NYHA class II-III obstructive HCM.
Mavacamten works by targeting the heart muscle’s contractile function.
Section 12.1 Mechanism of Action: myosin inhibition/allosteric inhibition selective for cardiac myosin, modulating cross-bridge formation.
Mavacamten helps reduce abnormal heart muscle contraction in people with obstructive HCM.
Section 12.1 Mechanism of Action: reduces probability of force-producing (systolic) and residual (diastolic) cross-bridge formation.
Mavacamten helps improve symptoms in people with obstructive HCM.
Section 1 INDICATIONS AND USAGE: improve functional capacity and symptoms; and Section 14 clinical studies discuss symptom/functional outcomes (e.g., KCCQ-23 CSS; NYHA class improvement).
Mavacamten relaxes the overly strong contraction of the heart muscle by modulating the way heart muscle proteins interact during contraction.
Section 12.1 Mechanism of Action: allosteric reversible inhibitor selective for cardiac myosin; modulates myosin heads entering on-actin states and cross-bridge formation.
Mavacamten is intended to reduce obstruction in the left ventricular outflow tract in obstructive HCM.
Section 12.1 Mechanism of Action: reduces dynamic LVOT obstruction; and Section 14: LVOT gradient endpoints.
Mavacamten is for people with hypertrophic cardiomyopathy that is obstructive.
Section 1 INDICATIONS AND USAGE: indicated for obstructive HCM.
Mavacamten treatment is associated with reductions in the left ventricular outflow tract gradient as a measure of obstruction severity.
Section 14: EXPLORER-HCM reports post-exercise LVOT gradient change favoring CAMZYOS (Table 3) and VALOR-HCM uses LVOT gradient criteria/endpoints (Table 6).
Mavacamten treatment is associated with improvements in exercise tolerance and quality of life measures as outcomes reflecting obstruction severity.
Section 14: EXPLORER-HCM includes pVO2 (exercise capacity) and health status measures including KCCQ-23 and HCMSQ with greater improvement vs placebo.
Mavacamten changes contractility.
Supported indirectly by Section 12.1: myosin inhibition reduces force-producing cross-bridge formation (mechanistic effect on contractile function).
Mavacamten is sold under the brand name Camzyos.
Label excerpts use CAMZYOS as product name (e.g., Section 1 INDICATIONS AND USAGE).
Unsupported Statements
Mavacamten is typically considered when symptoms are related to obstruction.
Not supported by the provided label excerpts (no statement in provided text about typical consideration criteria beyond the indication statement).
Mavacamten is considered when clinicians aim to reduce the outflow gradient and improve functional capacity.
Not explicitly supported by provided excerpts; indication/improvement claims exist, but phrasing about clinician aiming is not directly stated.
Patients and clinicians focus on symptom improvement with mavacamten.
The label indicates symptom improvement, but does not state this behavioral focus.
Clinicians monitor patients for tolerability while on therapy with mavacamten.
Monitoring/tolerability is not stated in the provided excerpts.
Dosing and adjustments of mavacamten depend on patient response.
Dosing adjustment rationale is described in EXPLORER-HCM as periodic adjustment to optimize response, but the provided excerpt does not include a general prescribing statement that dosing adjustments depend on patient response (beyond trial description).
Dosing and adjustments of mavacamten depend on how the drug affects cardiac function.
Although the EXPLORER-HCM excerpt mentions maintaining LVEF ≥50% and optimizing LVOT gradient, the provided label excerpts do not provide general dosing adjustment instructions framed as dependent on drug effect on cardiac function.
Clinicians manage mavacamten treatment by monitoring outcomes tied to effectiveness and safety.
Not explicitly supported in provided excerpts.
If the heart becomes underpowered with mavacamten, symptoms can occur.
Not supported by provided excerpts; relevant warnings/precautions section text was not provided.
If outflow obstruction is reduced excessively with mavacamten, symptoms can occur.
Not supported by provided excerpts; relevant warnings/precautions section text was not provided.
Monitoring during mavacamten treatment is used to reduce the risk of such events where the heart becomes underpowered or obstruction is reduced excessively.
Not supported by provided excerpts; monitoring and specific risk language are absent.
Dosing may need adjustment based on clinical and echocardiographic findings during mavacamten treatment.
The EXPLORER-HCM excerpt mentions periodic dose adjustments informed by LVOT gradient and LVEF, and VALOR-HCM states dose adjustment based on clinical echocardiogram parameters, but the claim is a generalization about dosing during treatment rather than a clearly labeled dosing/administration instruction in the excerpts.
Mavacamten is an established therapy in obstructive HCM.
Not supported by provided label excerpts.
Contradictions
Important Omissions
Boxed warnings (if any) and full warnings/precautions content were not provided, so safety statements and monitoring requirements cannot be fully verified against the label.
Importance:
High
Contraindications were not provided, so any implicit contraindication-related claims (or lack thereof) cannot be assessed.
Importance:
Moderate
Formal dosing/administration instructions (including initiation/adjustment schedules, REMS, specific monitoring intervals, lab/echo requirements, drug-drug interaction management) were not provided.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several safety/monitoring and dosing adjustment claims are not supported by the provided prescribing-information excerpts, and key sections (warnings/precautions/dosing/administration) were not included for verification.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Unsupported generalized safety/monitoring and dosing-adjustment rationales (e.g., underpowered heart; excessive obstruction reduction) not supported by provided excerpts.
Suggested Improvement
Limit claims to the provided label excerpts (indication, mechanism effects on LVOT obstruction/cross-bridge formation, and trial-reported outcomes) and avoid asserting specific warning/monitoring or dosing adjustment rationales unless the corresponding warnings/precautions and dosing/administration sections are provided.